Berman Capital Advisors’s Travere Therapeutics TVTX Stock Holding History

Berman Capital Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$10K	Sell	423 -51	-11%	-$937	﹤0.01%	1198
2021 Q2	$6K	Sell	474 -16	-3%	-$316	﹤0.01%	1310
2021 Q1	$12K	Hold	490	–	–	﹤0.01%	977
2020 Q4	$13K	Hold	490	–	–	﹤0.01%	833
2020 Q3	$9K	Hold	490	–	–	﹤0.01%	853
2020 Q2	$10K	Buy	490 +67	+16%	+$1.07K	﹤0.01%	776
2020 Q1	$6K	Hold	423	–	–	﹤0.01%	854
2019 Q4	$6K	Buy	+423	New	+$5.4K	﹤0.01%	939

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Berman Capital Advisors's TVTX Position: Q3 2021 in Review

Berman Capital Advisors reduced its Travere Therapeutics (TVTX) stake by 11% in Q3 2021, selling an estimated $937 and leaving 423 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1198.

Berman Capital Advisors first reported a position in TVTX in Q4 2019 and has held it in 8 quarters since. The position peaked at $13K in Q4 2020. 148 funds tracked by Wall St. Rank hold TVTX as of Q3 2021.

Berman Capital Advisors held 423 shares of Travere Therapeutics worth $10K as of Q3 2021.
Berman Capital Advisors sold 51 Travere Therapeutics shares in Q3 2021, an estimated $937.
Travere Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1198 holding.
Berman Capital Advisors first reported a position in Travere Therapeutics in Q4 2019 and has held it in 8 quarters since.
Berman Capital Advisors's Travere Therapeutics position peaked at $13K in Q4 2020.
148 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.